Evidence map›Paper›PMID 40863621›Full record

ArticleMarine drugs2025

Antitumor Activity of

Mengyue Liu, Weixia Wang, Haoran Wang, Shuang Zhao, Dongli Yin, Haijun Zhang, Chunze Zou, Shengcan Zou, Jia Yu, Yuxi Wei

Abstract read
In one paragraph

Article in Marine drugs, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mengyue LiuCollege of Life Sciences, Qingdao University, Qingdao 266071, China.
Weixia WangQingdao Yihai Industry Holdings Co., Ltd., Qingdao 266105, China.
Haoran WangCollege of Materials Science and Engineering, Qingdao University, Qingdao 266071, China.
Shuang ZhaoCollege of Life Sciences, Qingdao University, Qingdao 266071, China.
Dongli YinQingdao Yihai Industry Holdings Co., Ltd., Qingdao 266105, China.
Haijun ZhangQingdao Yihai Industry Holdings Co., Ltd., Qingdao 266105, China.
Chunze ZouDonald Bren School of Information and Computer Sciences, University of California, Irvine, CA 92697, USA.
Shengcan ZouQingdao Yihai Industry Holdings Co., Ltd., Qingdao 266105, China.
Jia YuCollege of Life Sciences, Qingdao University, Qingdao 266071, China.ORCID 0000-0002-8366-2960
Yuxi WeiCollege of Life Sciences, Qingdao University, Qingdao 266071, China.ORCID 0000-0002-0616-479X

Funding

Natural Science Foundation of Shandong Province ZR202211230270Taishan Industrial Leading Talents Project-Blue Talent Special (2021) No
6 · The paper itself

Abstract

Colorectal cancer (CRC) remains a predominant cause of global cancer-related mortality, highlighting the pressing demand for innovative therapeutic strategies. Natural polysaccharides have emerged as promising candidates in cancer research due to their multifaceted anticancer mechanisms and tumor-suppressive potential across diverse malignancies. In this study, we enzymatically extracted a polysaccharide, named ERPP, from

Indexed as

Antineoplastic AgentsApoptosisBivalviaColorectal NeoplasmsMitochondriaPolysaccharidesAnimalsCell ProliferationHT29 CellsHumansMembrane Potential, MitochondrialReactive Oxygen SpeciesXenograft Model Antitumor AssaysZebrafishAntineoplastic AgentsPolysaccharidesReactive Oxygen Speciesanti-colorectal cancer activitymitochondrial apoptosisRuditapes philippinarum polysaccharideszebrafish

Identifiers

PMID40863621
PMCPMC12387552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.